An observational study to discover novel biomarkers for nivolumab in patients with advanced gastric cancer (DELIVER trial): JACCRO GC-08

Conditions

Gastric cancer

Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru et al. (18 authors)

Journal of Clinical Oncology2023-06-01

10.1200/jco.2023.41.16_suppl.4039

Abstract 5957: Molecular characteristics of gut microbiota in patients with gastric cancer: The DELIVER trial (JACCRO GC-08)

Ryo Matoba, Hiroshi Iijima, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro et al. (25 authors)

Cancer Research2022-06-15

10.1158/1538-7445.am2022-5957

Yu Sunakawa, Ryo Matoba, T. Takayama, Naoki Okumura, Naotoshi Sugimoto et al. (20 authors)

Journal of Clinical Oncology2022-01-191 citations

10.1200/jco.2022.40.4_suppl.245

Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

Yosuke Kito, Eisuke Inoue, Yusuke Akamaru, Masazumi Takahashi, Jin Matsuyama et al. (20 authors)

Journal of Clinical Oncology2021-05-20

10.1200/jco.2021.39.15_suppl.4044

Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).

Yu Sunakawa, Ryo Matoba, Eisuke Inoue, Yasuhiro Sakamoto, Ryohei Kawabata et al. (20 authors)

Journal of Clinical Oncology2021-01-2024 citations

10.1200/jco.2021.39.3_suppl.161

Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: Real-world data from a large observational/translational study, JACCRO GC-08 (deliver trial).

Ryohei Kawabata, Yasuhiro Sakamoto, Eisuke Inoue, Atsushi Ishiguro, Yusuke Akamaru et al. (20 authors)

Journal of Clinical Oncology2020-05-20

10.1200/jco.2020.38.15_suppl.4527

DELIVER (JACCRO GC-08) Trial: Discover Novel Host-Related Immune-Biomarkers for Nivolumab in Advanced Gastric Cancer

Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Hisato Kawakami, Yoshiharu Sato et al. (9 authors)

Future Oncology2019-05-2911 citations

10.2217/fon-2019-0167

A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial)

Yu Sunakawa, Kei Muro, Takako Eguchi Nakajima, Hisato Kawakami, Eisuke Inoue et al. (9 authors)

Annals of Oncology2018-12-01

10.1093/annonc/mdy493.027

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with histologically confirmed diagnosis of adenocarcinoma of the GEJ/gastric cancer. (2) Patients treated with nivolumab alone treatment (in any lines). (3) ECOG performance status 0-2. (4) 20 years of age or more. (5) Patients with potential to collect feces and blood before and after nivolumab treatment. (6) Written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients previously treated with nivolumab (2) HBs antigen-positive or HCV antibody-positive (3) Patients who are regarded as inadequate for study enrollment by investigators.

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
Response Rate, Disease Control Rate, Depth of Response, Tumor Shrinkage Rate, Tumor Progression Rate, Progression-Free Survival, Safety, Biomarker Analysis	—

Countries

Japan

Contacts

Public ContactMasashi Fujii

Japan Clinical Cancer Reseach Organization (JACCRO) Research Office

gc08.dc@jaccro.or.jp03-6811-0433

Outcome results